|
1
|
Chen J, Jiang CC, Jin L and Zhang XD:
Regulation of PD-L1: A novel role of pro-survival signalling in
cancer. Ann Oncol. 27:409–416. 2016. View Article : Google Scholar
|
|
2
|
Mellman I, Coukos G and Dranoff G: Cancer
immunotherapy comes of age. Nature. 480:480–489. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Guan J, Lim KS, Mekhail T and Chang CC:
Programmed death ligand-1 (PD-L1) expression in the programmed
death receptor-1 (PD-1)/PD-L1 blockade: A key player against
various cancers. Arch Pathol Lab Med. 141:851–861. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dong H, Strome SE, Salomao DR, Tamura H,
Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al:
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential
mechanism of immune evasion. Nat Med. 8:793–800. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yang F, Wang JF, Wang Y, Liu B and Molina
JR: Comparative analysis of predictive biomarkers for PD-1/PD-L1
inhibitors in cancers: Developments and challenges. Cancers.
14:1092021. View Article : Google Scholar
|
|
6
|
Liu D, Wang S and Bindeman W: Clinical
applications of PD-L1 bioassays for cancer immunotherapy. J Hematol
Oncol. 10:1102017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang Y, Zhang H, Liu C, Wang Z, Wu W,
Zhang N, Zhang L, Hu J, Luo P, Zhang J, et al: Immune checkpoint
modulators in cancer immunotherapy: Recent advances and emerging
concepts. J Hematol Oncol. 15:1112022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kim CG, Kim M, Hwang J, Kim ST, Jung M,
Kim KH, Kim KH, Chang JS, Koom WS, Roh MR, et al: First-line
pembrolizumab versus dabrafenib/trametinib treatment for BRAF
V600-mutant advanced melanoma. J Am Acad Dermatol. Sep 3–2022.Epub
ahead of print. View Article : Google Scholar
|
|
9
|
Donne R and Lujambio A: The liver cancer
immune microenvironment: Therapeutic Implications for
hepatocellular carcinoma. Hepatology. Aug 21–2022.Epub ahead of
print. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sun C, Mezzadra R and Schumacher TN:
Regulation and function of the PD-L1 checkpoint. Immunity.
48:434–452. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Topalian SL, Drake CG and Pardoll DM:
Immune checkpoint blockade: A common denominator approach to cancer
therapy. Cancer Cell. 27:450–461. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang H, Fu C, Du J, Wang H, He R, Yin X,
Li H, Li X, Wang H, Li K, et al: Enhanced histone H3 acetylation of
the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for
PD-L1 expression in drug-resistant cancer cells. J Exp Clin Cancer
Res. 39:292020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sharma P, Hu-Lieskovan S, Wargo JA and
Ribas A: Primary, adaptive, and acquired resistance to cancer
immunotherapy. Cell. 168:707–723. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Burkitt K and Saloura V: Epigenetic
modifiers as novel therapeutic targets and a systematic review of
clinical studies investigating epigenetic inhibitors in head and
neck cancer. Cancers (Basel). 13:52412021. View Article : Google Scholar
|
|
15
|
Huo M, Zhang J, Huang W and Wang Y:
Interplay among metabolism, epigenetic modifications, and gene
expression in cancer. Front Cell Dev Biol. 9:7934282021. View Article : Google Scholar
|
|
16
|
Perrier A, Didelot A, Laurent-Puig P,
Blons H and Garinet S: Epigenetic mechanisms of resistance to
immune checkpoint inhibitors. Biomolecules. 10:10612020. View Article : Google Scholar :
|
|
17
|
Martínez-Cano J, Campos-Sánchez E and
Cobaleda C: Epigenetic priming in immunodeficiencies. Front Cell
Dev Biol. 7:1252019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kuendgen A and Lübbert M: Current status
of epigenetic treatment in myelodysplastic syndromes. Ann Hematol.
87:601–611. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hoy SM: Tazemetostat: First approval.
Drugs. 80:513–521. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li Y and Seto E: HDACs and HDAC inhibitors
in cancer development and therapy. Cold Spring Harb Perspect Med.
6:a0268312016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen Y, Liu X, Li Y, Quan C, Zheng L and
Huang K: Lung cancer therapy targeting histone methylation:
Opportunities and challenges. Comput Struct Biotechnol J.
16:211–223. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lei Q, Wang D, Sun K, Wang L and Zhang Y:
Resistance mechanisms of anti-PD1/PDL1 therapy in solid tumors.
Front Cell Dev Biol. 8:6722020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
O'Donnell JS, Long GV, Scolyer RA, Teng MW
and Smyth MJ: Resistance to PD1/PDL1 checkpoint inhibition. Cancer
Treat Rev. 52:71–81. 2017. View Article : Google Scholar
|
|
24
|
Shen Y, Liu L, Wang M, Xu B, Lyu R, Shi YG
and Tan L: TET2 inhibits PD-L1 gene expression in breast cancer
cells through histone deacetylation. Cancers (Basel). 13:22072021.
View Article : Google Scholar
|
|
25
|
Fan P, Zhao J, Meng Z, Wu H, Wang B, Wu H
and Jin X: Overexpressed histone acetyltransferase 1 regulates
cancer immunity by increasing programmed death-ligand 1 expression
in pancreatic cancer. J Exp Clin Cancer Res. 38:472019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lu C, Paschall AV, Shi H, Savage N, Waller
JL, Sabbatini ME, Oberlies NH, Pearce C and Liu K: The MLL1-H3K4me3
axis-mediated PD-L1 expression and pancreatic cancer immune
evasion. J Natl Cancer Inst. 109:djw2832017. View Article : Google Scholar :
|
|
27
|
Xia R, Geng G, Yu X, Xu Z, Guo J, Liu H,
Li N, Li Z, Li Y, Dai X, et al: LINC01140 promotes the progression
and tumor immune escape in lung cancer by sponging multiple
microRNAs. J Immunother Cancer. 9:e0027462021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gilles ME and Slack FJ: Let-7 microRNA as
a potential therapeutic target with implications for immunotherapy.
Expert Opin Ther Targets. 22:929–939. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hou J, Huang Q, Fan Z, Sang H, Wu S, Cheng
S and Li Q: LncRNA OIP5-AS1 knockdown facilitated the ferroptosis
and immune evasion by modulating the GPX4 in oesophageal carcinoma.
Comput Math Methods Med. 2022:81031982022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang X, Liang C, Yao X, Yang RH, Zhang ZS,
Liu FY, Li WQ, Pei SH, Ma J, Xie SQ and Fang D: Corrigendum:
PKM2-induced the phosphorylation of histone H3 contributes to
EGF-Mediated PD-L1 transcription in HCC. Front Pharmacol.
12:7247992021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chung HC, Ros W, Delord JP, Perets R,
Italiano A, Shapira-Frommer R, Manzuk L, Piha-Paul SA, Xu L,
Zeigenfuss S, et al: Efficacy and safety of pembrolizumab in
previously treated advanced cervical cancer: Results from the phase
II KEYNOTE-158 study. J Clin Oncol. 37:1470–1478. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Abiko K, Hamanishi J, Matsumura N and
Mandai M: Dynamic host immunity and PD-L1/PD-1 blockade efficacy:
Developments after 'IFN-γ from lymphocytes induces PD-L1 expression
and promotes progression of ovarian cancer'. Br J Cancer. Sep
6–2022.Epub ahead of print. View Article : Google Scholar
|
|
33
|
Mussafi O, Mei J, Mao W and Wan Y: Immune
checkpoint inhibitors for PD-1/PD-L1 axis in combination with other
immunotherapies and targeted therapies for non-small cell lung
cancer. Front Oncol. 12:9484052022. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Garcia-Diaz A, Shin DS, Moreno BH, Saco J,
Escuin-Ordinas H, Rodriguez GA, Zaretsky JM, Sun L, Hugo W, Wang X,
et al: Interferon receptor signaling pathways regulating PD-L1 and
PD-L2 expression. Cell Rep. 29:37662019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ribas A and Wolchok JD: Cancer
immunotherapy using checkpoint blockade. Science. 359:1350–1355.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Akinleye A and Rasool Z: Immune checkpoint
inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol.
12:922019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Heemskerk B, Kvistborg P and Schumacher
TN: The cancer antigenome. EMBO J. 32:194–203. 2013. View Article : Google Scholar :
|
|
38
|
McLane LM, Abdel-Hakeem MS and Wherry EJ:
CD8 T cell exhaustion during chronic viral infection and cancer.
Annu Rev Immunol. 37:457–495. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang Z, Liu S, Zhang B, Qiao L and Zhang
Y and Zhang Y: T cell dysfunction and exhaustion in cancer. Front
Cell Dev Biol. 8:172020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sade-Feldman M, Jiao YJ, Chen JH, Rooney
MS, Barzily-Rokni M, Eliane JP, Bjorgaard SL, Hammond MR, Vitzthum
H, Blackmon SM, et al: Resistance to checkpoint blockade therapy
through inactivation of antigen presentation. Nat Commun.
8:11362017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yeon Yeon S, Jung SH, Jo YS, Choi EJ, Kim
MS, Chung YJ and Lee SH: Immune checkpoint blockade
resistance-related B2M hotspot mutations in microsatellite-unstable
colorectal carcinoma. Pathol Res Pract. 215:209–214. 2019.
View Article : Google Scholar
|
|
42
|
Ngiow SF, Young A, Jacquelot N, Yamazaki
T, Enot D, Zitvogel L and Smyth MJ: A threshold level of intratumor
CD8+ T-cell PD1 expression dictates therapeutic response to
anti-PD1. Cancer Res. 75:3800–3811. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Li X, Wenes M, Romero P, Huang SC, Fendt
SM and Ho PC: Navigating metabolic pathways to enhance antitumour
immunity and immunotherapy. Nat Rev Clin Oncol. 16:425–441. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
O'Donnell JS, Teng MWL and Smyth MJ:
Cancer immunoediting and resistance to T cell-based immunotherapy.
Nat Rev Clin Oncol. 16:151–167. 2019. View Article : Google Scholar
|
|
45
|
Pauken KE, Sammons MA, Odorizzi PM, Manne
S, Godec J, Khan O, Drake AM, Chen Z, Sen DR, Kurachi M, et al:
Epigenetic stability of exhausted T cells limits durability of
reinvigoration by PD-1 blockade. Science. 354:1160–1165. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Theivanthiran B, Evans KS, DeVito NC,
Plebanek M, Sturdivant M, Wachsmuth LP, Salama AK, Kang Y, Hsu D,
Balko JM, et al: A tumor-intrinsic PD-L1/NLRP3 inflammasome
signaling pathway drives resistance to anti-PD-1 immunotherapy. J
Clin Invest. 130:2570–2586. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Bowman GD and Poirier MG:
Post-translational modifications of histones that influence
nucleosome dynamics. Chem Rev. 115:2274–2295. 2015. View Article : Google Scholar :
|
|
48
|
Bajbouj K, Al-Ali A, Ramakrishnan RK,
Saber-Ayad M and Hamid Q: Histone modification in NSCLC: Molecular
mechanisms and therapeutic targets. Int J Mol Sci. 22:117012021.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Hu X, Lin Z, Wang Z and Zhou Q: Emerging
role of PD-L1 modification in cancer immunotherapy. Am J Cancer
Res. 11:3832–3840. 2021.PubMed/NCBI
|
|
50
|
Greer EL and Shi Y: Histone methylation: A
dynamic mark in health, disease and inheritance. Nat Rev Genet.
13:343–357. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Li W, Wu H, Sui S, Wang Q, Xu S and Pang
D: Targeting histone modifications in breast cancer: A precise
weapon on the way. Front Cell Dev Biol. 9:7369352021. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Shi Y, Fu Y, Zhang X, Zhao G, Yao Y, Guo
Y, Ma G, Bai S and Li H: Romidepsin (FK228) regulates the
expression of the immune checkpoint ligand PD-L1 and suppresses
cellular immune functions in colon cancer. Cancer Immunol
Immunother. 70:61–73. 2021. View Article : Google Scholar :
|
|
53
|
Zingg D, Arenas-Ramirez N, Sahin D,
Rosalia RA, Antunes AT, Haeusel J, Sommer L and Boyman O: The
histone methyltransferase Ezh2 controls mechanisms of adaptive
resistance to tumor immunotherapy. Cell Rep. 20:854–867. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Gallagher SJ, Tiffen JC and Hersey P:
Histone modifications, modifiers and readers in melanoma resistance
to targeted and immune therapy. Cancers (Basel). 7:1959–1982. 2015.
View Article : Google Scholar
|
|
55
|
Deng S, Hu Q, Zhang H, Yang F, Peng C and
Huang C: HDAC3 inhibition upregulates PD-L1 expression in B-cell
lymphomas and augments the efficacy of anti-PD-L1 therapy. Mol
Cancer Ther. 18:900–908. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Mondello P, Tadros S, Teater M, Fontan L,
Chang AY, Jain N, Yang H, Singh S, Ying HY, Chu CS, et al:
Selective inhibition of HDAC3 targets synthetic vulnerabilities and
activates immune surveillance in lymphoma. Cancer Discov.
10:440–459. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Hashimoto S, Hashimoto A, Muromoto R,
Kitai Y, Oritani K and Matsuda T: Central roles of STAT3-mediated
signals in onset and development of cancers: Tumorigenesis and
immunosurveillance. Cells. 11:26182022. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Hu G, He N, Cai C, Cai F, Fan P, Zheng Z
and Jin X: HDAC3 modulates cancer immunity via increasing PD-L1
expression in pancreatic cancer. Pancreatology. 19:383–389. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Wang YF, Liu F, Sherwin S, Farrelly M, Yan
XG, Croft A, Liu T, Jin L, Zhang XD and Jiang CC: Cooperativity of
HOXA5 and STAT3 is critical for HDAC8 inhibition-mediated
transcriptional activation of PD-L1 in human melanoma cells. J
Invest Dermatol. 138:922–932. 2018. View Article : Google Scholar
|
|
60
|
ML PPV, TK MP, ES JP, KVW CL, FC SD, et
al: Essential role of HDAC6 in the regulation of PD-L1 in melanoma.
Mol Oncol. 10:735–750. 2016. View Article : Google Scholar
|
|
61
|
Keremu A, Aimaiti A, Liang Z and Zou X:
Role of the HDAC6/STAT3 pathway in regulating PD-L1 expression in
osteosarcoma cell lines. Cancer Chemother Pharmacol. 83:255–264.
2019. View Article : Google Scholar
|
|
62
|
Yano M, Katoh T, Miyazawa M, Miyazawa M,
Ogane N, Miwa M, Hasegawa K, Narahara H and Yasuda M:
Clinicopathological correlation of ARID1A status with HDAC6 and its
related factors in ovarian clear cell carcinoma. Sci Rep.
9:23972019. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Liu X, Wang Y, Zhang R, Jin T, Qu L, Jin
Q, Zheng J, Sun J, Wu Z, Wang L, et al: HDAC10 is positively
associated with PD-L1 expression and poor prognosis in patients
with NSCLC. Front Oncol. 10:4852020. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Xu P, Xiong W, Lin Y, Fan L, Pan H and Li
Y: Histone deacetylase 2 knockout suppresses immune escape of
triple-negative breast cancer cells via downregulating PD-L1
expression. Cell Death Dis. 12:7792021. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Darvin P, Sasidharan Nair V and Elkord E:
PD-L1 expression in human breast cancer stem cells is
epigenetically regulated through posttranslational histone
modifications. J Oncol. 2019:39589082019. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Makowski AM, Dutnall RN and Annunziato AT:
Effects of acetylation of histone H4 at lysines 8 and 16 on
activity of the Hat1 histone acetyltransferase. J Biol Chem.
276:43499–43502. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Jin X, Tian S and Li P: Histone
acetyltransferase 1 promotes cell proliferation and induces
cisplatin resistance in hepatocellular carcinoma. Oncol Res.
25:939–946. 2017. View Article : Google Scholar
|
|
68
|
Halaburková A, Jendželovský R, Kovaľ J,
Herceg Z, Fedoročko P and Ghantous A: Histone deacetylase
inhibitors potentiate photodynamic therapy in colon cancer cells
marked by chromatin-mediated epigenetic regulation of CDKN1A. Clin
Epigenetics. 9:622017. View Article : Google Scholar :
|
|
69
|
Maccallini C, Ammazzalorso A, De Filippis
B, Fantacuzzi M, Giampietro L and Amoroso R: HDAC inhibitors for
the therapy of triple negative breast cancer. Pharmaceuticals
(Basel). 15:6672022. View Article : Google Scholar
|
|
70
|
Knox T, Sahakian E, Banik D, Hadley M,
Palmer E, Noonepalle S, Kim J, Powers J, Gracia-Hernandez M,
Oliveira V, et al: Author correction: Selective HDAC6 inhibitors
improve anti-PD-1 immune checkpoint blockade therapy by decreasing
the anti-inflammatory phenotype of macrophages and down-regulation
of immunosuppressive proteins in tumor cells. Sci Rep. 9:148242019.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Briere D, Sudhakar N, Woods DM, Hallin J,
Engstrom LD, Aranda R, Chiang H, Sodré AL, Olson P, Weber JS and
Christensen JG: The class I/IV HDAC inhibitor mocetinostat
increases tumor antigen presentation, decreases immune suppressive
cell types and augments checkpoint inhibitor therapy. Cancer
Immunol Immunother. 67:381–392. 2018. View Article : Google Scholar
|
|
72
|
Que Y, Zhang XL, Liu ZX, Zhao JJ, Pan QZ,
Wen XZ, Xiao W, Xu BS, Hong DC, Guo TH, et al: Frequent
amplification of HDAC genes and efficacy of HDAC inhibitor
chidamide and PD-1 blockade combination in soft tissue sarcoma. J
Immunother Cancer. 9:e0016962021. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Sheikh TN, Chen X, Xu X, McGuire JT,
Ingham M, Lu C and Schwartz GK: Growth inhibition and induction of
innate immune signaling of chondrosarcomas with epigenetic
inhibitors. Mol Cancer Ther. 20:2362–2371. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Huang R, Zhang X, Min Z, Shadia AS, Yang S
and Liu X: MGCD0103 induces apoptosis and simultaneously increases
the expression of NF-κB and PD-L1 in classical Hodgkin's lymphoma.
Exp Ther Med. 16:3827–3834. 2018.PubMed/NCBI
|
|
75
|
Woods DM, Sodré AL, Villagra A, Sarnaik A,
Sotomayor EM and Weber J: HDAC inhibition upregulates PD-1 ligands
in melanoma and augments immunotherapy with PD-1 blockade. Cancer
Immunol Res. 3:1375–1385. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Liu J, He D, Cheng L, Huang C, Zhang Y,
Rao X, Kong Y, Li C, Zhang Z, Liu J, et al: p300/CBP inhibition
enhances the efficacy of programmed death-ligand 1 blockade
treatment in prostate cancer. Oncogene. 39:3939–3951. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Bissonnette RP, Cesario RM, Goodenow B,
Shojaei F and Gillings M: The epigenetic immunomodulator, HBI-8000,
enhances the response and reverses resistance to checkpoint
inhibitors. BMC Cancer. 21:9692021. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Chen MC, Lin YC, Liao YH, Liou JP and Chen
CH: MPT0G612, a novel HDAC6 inhibitor, induces apoptosis and
suppresses IFN-γ-induced programmed death-ligand 1 in human
colorectal carcinoma cells. Cancers (Basel). 11:16172019.
View Article : Google Scholar
|
|
79
|
Shin HS, Choi J, Lee J and Lee SY: Histone
deacetylase as a valuable predictive biomarker and therapeutic
target in immunotherapy for non-small cell lung cancer. Cancer Res
Treat. 54:458–468. 2022. View Article : Google Scholar
|
|
80
|
Kuroki H, Anraku T, Kazama A, Shirono Y,
Bilim V and Tomita Y: Histone deacetylase 6 inhibition in
urothelial cancer as a potential new strategy for cancer treatment.
Oncol Lett. 21:642021. View Article : Google Scholar
|
|
81
|
Hai R, Yang D, Zheng F, Wang W, Han X,
Bode AM and Luo X: The emerging roles of HDACs and their
therapeutic implications in cancer. Eur J Pharmacol.
931:1752162022. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Xia C, Leon-Ferre R, Laux D, Deutsch J,
Smith BJ, Frees M and Milhem M: Treatment of resistant metastatic
melanoma using sequential epigenetic therapy (decitabine and
panobinostat) combined with chemotherapy (temozolomide). Cancer
Chemother Pharmacol. 74:691–697. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Barski A, Cuddapah S, Cui K, Roh TY,
Schones DE, Wang Z, Wei G, Chepelev I and Zhao K: High-resolution
profiling of histone methylations in the human genome. Cell.
129:823–837. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Sasidharan Nair V, Saleh R, Toor SM, Taha
RZ, Ahmed AA, Kurer MA, Murshed K, Abu Nada M and Elkord E:
Epigenetic regulation of immune checkpoints and T cell exhaustion
markers in tumor-infiltrating T cells of colorectal cancer
patients. Epigenomics. 12:1871–1882. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Bedford MT and Richard S: Arginine
methylation an emerging regulator of protein function. Mol Cell.
18:263–272. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Jiang Y, Yuan Y, Chen M, Li S, Bai J,
Zhang Y, Sun Y, Wang G, Xu H, Wang Z, et al: PRMT5 disruption
drives antitumor immunity in cervical cancer by reprogramming T
cell-mediated response and regulating PD-L1 expression.
Theranostics. 11:9162–9176. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Zhou Q, Chen X, He H, Peng S, Zhang Y,
Zhang J, Cheng L, Liu S, Huang M, Xie R, et al: WD repeat domain 5
promotes chemoresistance and programmed death-ligand 1 expression
in prostate cancer. Theranostics. 11:4809–4824. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Kim KH and Roberts CW: Targeting EZH2 in
cancer. Nat Med. 22:128–134. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Zhao Y, Wang XX, Wu W, Long H, Huang J,
Wang Z, Li T, Tang S, Zhu B and Chen D: EZH2 regulates PD-L1
expression via HIF-1α in non-small cell lung cancer cells. Biochem
Biophys Res Commun. 517:201–209. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Liu L, Yu T, Jin Y, Mai W, Zhou J and Zhao
C: MicroRNA-15a carried by mesenchymal stem cell-derived
extracellular vesicles inhibits the immune evasion of colorectal
cancer cells by regulating the KDM4B/HOXC4/PD-L1 axis. Front Cell
Dev Biol. 9:6298932021. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Soldi R, Ghosh Halder T, Weston A, Thode
T, Drenner K, Lewis R, Kaadige MR, Srivastava S, Daniel Ampanattu
S, Rodriguez Del Villar R, et al: The novel reversible LSD1
inhibitor SP-2577 promotes anti-tumor immunity in
SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian
cancer. PLoS One. 15:e02357052020. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Qin Y, Vasilatos SN, Chen L, Wu H, Cao Z,
Fu Y, Huang M, Vlad AM, Lu B, Oesterreich S, et al: Inhibition of
histone lysine-specific demethylase 1 elicits breast tumor immunity
and enhances antitumor efficacy of immune checkpoint blockade.
Oncogene. 38:390–405. 2019. View Article : Google Scholar :
|
|
93
|
Liu J, Zhao Z, Qiu N, Zhou Q, Wang G,
Jiang H, Piao Y, Zhou Z, Tang J and Shen Y: Co-delivery of IOX1 and
doxorubicin for antibody-independent cancer chemo-immunotherapy.
Nat Commun. 12:24252021. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Olsen JV, Vermeulen M, Santamaria A, Kumar
C, Miller ML, Jensen LJ, Gnad F, Cox J, Jensen TS, Nigg EA, et al:
Quantitative phosphoproteomics reveals widespread full
phosphorylation site occupancy during mitosis. Sci Signal.
3:ra32010. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Schmitz ML, Higgins JMG and Seibert M:
Priming chromatin for segregation: Functional roles of mitotic
histone modifications. Cell Cycle. 19:625–641. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Santaguida S and Amon A: Short- and
long-term effects of chromosome mis-segregation and aneuploidy. Nat
Rev Mol Cell Biol. 16:473–485. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Cerutti H and Casas-Mollano JA: Histone H3
phosphorylation: Universal code or lineage specific dialects?
Epigenetics. 4:71–75. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Chen S, Youhong T, Tan Y, He Y, Ban Y, Cai
J, Li X, Xiong W, Zeng Z, Li G, et al: EGFR-PKM2 signaling promotes
the metastatic potential of nasopharyngeal carcinoma through
induction of FOSL1 and ANTXR2. Carcinogenesis. 41:723–733. 2020.
View Article : Google Scholar :
|
|
99
|
Wang WT, Han C, Sun YM, Chen TQ and Chen
YQ: Noncoding RNAs in cancer therapy resistance and targeted drug
development. J Hematol Oncol. 12:552019. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Kaur M, Kaur B, Konar M and Sharma S:
Noncoding RNAs as novel immunotherapeutic tools against cancer. Adv
Protein Chem Struct Biol. 129:135–161. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Rolfo C, Fanale D, Hong DS, Tsimberidou
AM, Piha-Paul SA, Pauwels P, Van Meerbeeck JP, Caruso S, Bazan V,
Cicero G, et al: Impact of microRNAs in resistance to chemotherapy
and novel targeted agents in non-small cell lung cancer. Curr Pharm
Biotechnol. 15:475–485. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Schanza LM, Seles M, Stotz M, Fosselteder
J, Hutterer GC, Pichler M and Stiegelbauer V: MicroRNAs associated
with Von Hippel-Lindau pathway in renal cell carcinoma: A
comprehensive review. Int J Mol Sci. 18:24952017. View Article : Google Scholar
|
|
103
|
Forterre A, Komuro H, Aminova S and Harada
M: A comprehensive review of cancer MicroRNA therapeutic delivery
strategies. Cancers (Basel). 12:18522020. View Article : Google Scholar
|
|
104
|
Anastasiadou E, Faggioni A, Trivedi P and
Slack FJ: The nefarious nexus of noncoding RNAs in cancer. Int J
Mol Sci. 19:20722018. View Article : Google Scholar :
|
|
105
|
Shi C and Zhang Z: The prognostic value of
the miR-200 family in ovarian cancer: A meta-analysis. Acta Obstet
Gynecol Scand. 95:505–512. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Cortez MA, Anfossi S, Ramapriyan R, Menon
H, Atalar SC, Aliru M, Welsh J and Calin GA: Role of miRNAs in
immune responses and immunotherapy in cancer. Genes Chromosomes
Cancer. 58:244–253. 2019. View Article : Google Scholar :
|
|
107
|
Tang D, Zhao D, Wu Y, Yao R, Zhou L, Lu L,
Gao W and Sun Y: The miR-3127-5p/p-STAT3 axis up-regulates PD-L1
inducing chemoresistance in non-small-cell lung cancer. J Cell Mol
Med. 22:3847–3856. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Chen Y, Xie C, Zheng X, Nie X, Wang Z, Liu
H and Zhao Y: LIN28/let-7/PD-L1 pathway as a target for cancer
immunotherapy. Cancer Immunol Res. 7:487–497. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Hong W, Xue M, Jiang J, Zhang Y and Gao X:
Circular RNA circ-CPA4/let-7 miRNA/PD-L1 axis regulates cell
growth, stemness, drug resistance and immune evasion in non-small
cell lung cancer (NSCLC). J Exp Clin Cancer Res. 39:1492020.
View Article : Google Scholar
|
|
110
|
Zhang Q, Pan J, Xiong D, Wang Y, Miller
MS, Sei S, Shoemaker RH, Izzotti A and You M: Pulmonary aerosol
delivery of Let-7b microRNA confers a striking inhibitory effect on
lung carcinogenesis through targeting the tumor immune
microenvironment. Adv Sci (Weinh). 8:e21006292021. View Article : Google Scholar
|
|
111
|
Xie WB, Liang LH, Wu KG, Wang LX, He X,
Song C, Wang YQ and Li YH: MiR-140 expression regulates cell
proliferation and targets PD-L1 in NSCLC. Cell Physiol Biochem.
46:654–663. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Jo H, Shim K and Jeoung D: Potential of
the miR-200 family as a target for developing anti-cancer
therapeutics. Int J Mol Sci. 23:58812022. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Katakura S, Kobayashi N, Hashimoto H,
Kamimaki C, Tanaka K, Kubo S, Nakashima K, Teranishi S, Manabe S,
Watanabe K, et al: MicroRNA-200b is a potential biomarker of the
expression of PD-L1 in patients with lung cancer. Thorac Cancer.
11:2975–2982. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Anastasiadou E, Messina E, Sanavia T,
Mundo L, Farinella F, Lazzi S, Megiorni F, Ceccarelli S, Pontecorvi
P, Marampon F, et al: MiR-200c-3p contrasts PD-L1 induction by
combinatorial therapies and slows proliferation of epithelial
ovarian cancer through downregulation of β-catenin and c-Myc.
Cells. 10:5192021. View Article : Google Scholar
|
|
115
|
Rogers TJ, Christenson JL, Greene LI,
O'Neill KI, Williams MM, Gordon MA, Nemkov T, D'Alessandro A,
Degala GD, Shin J, et al: Reversal of triple-negative breast cancer
EMT by miR-200c decreases tryptophan catabolism and a program of
immunosuppression. Mol Cancer Res. 17:30–41. 2019. View Article : Google Scholar
|
|
116
|
Yao Y, Kong X, Liu R, Xu F, Liu G and Sun
C: Development of a novel immune-related gene prognostic index for
breast cancer. Front Immunol. 13:8450932022. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Samanta D, Park Y, Ni X, Li H, Zahnow CA,
Gabrielson E, Pan F and Semenza GL: Chemotherapy induces enrichment
of CD47+/CD73+/PDL1+ immune
evasive triple-negative breast cancer cells. Proc Natl Acad Sci
USA. 115:E1239–E1248. 2018.
|
|
118
|
Dou D, Ren X, Han M, Xu X, Ge X, Gu Y and
Wang X: Cancer-associated fibroblasts-derived exosomes suppress
immune cell function in breast cancer via the miR-92/PD-L1 pathway.
Front Immunol. 11:20262020. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Zhang M, Shi Y, Zhang Y, Wang Y, Alotaibi
F, Qiu L, Wang H, Peng S, Liu Y, Li Q, et al: miRNA-5119 regulates
immune checkpoints in dendritic cells to enhance breast cancer
immunotherapy. Cancer Immunol Immunother. 69:951–967. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Wang LL, Huang WW, Huang J, Huang RF, Li
NN, Hong Y, Chen ML, Wu F and Liu J: Protective effect of
hsa-miR-570-3p targeting CD274 on triple negative breast cancer by
blocking PI3K/AKT/mTOR signaling pathway. Kaohsiung J Med Sci.
36:581–591. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Yang L, Cai Y, Zhang D, Sun J, Xu C, Zhao
W, Jiang W and Pan C: miR-195/miR-497 regulate CD274 expression of
immune regulatory ligands in triple-negative breast cancer. J
Breast Cancer. 21:371–381. 2018. View Article : Google Scholar
|
|
122
|
Li D, Wang X, Yang M, Kan Q and Duan Z:
miR3609 sensitizes breast cancer cells to adriamycin by blocking
the programmed death-ligand 1 immune checkpoint. Exp Cell Res.
380:20–28. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Liu J, Ren L, Li S, Li W, Zheng X, Yang Y,
Fu W, Yi J, Wang J and Du G: The biology, function, and
applications of exosomes in cancer. Acta Pharm Sin B. 11:2783–2797.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Mathivanan S, Ji H and Simpson RJ:
Exosomes: Extracellular organelles important in intercellular
communication. J Proteomics. 73:1907–1920. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Yao X, Tu Y, Xu Y, Guo Y, Yao F and Zhang
X: Endoplasmic reticulum stress-induced exosomal miR-27a-3p
promotes immune escape in breast cancer via regulating PD-L1
expression in macrophages. J Cell Mol Med. 24:9560–9573. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Li L, Cao B, Liang X, Lu S, Luo H, Wang Z,
Wang S, Jiang J, Lang J and Zhu G: Microenvironmental oxygen
pressure orchestrates an anti- and pro-tumoral γδ T cell
equilibrium via tumor-derived exosomes. Oncogene. 38:2830–2843.
2019. View Article : Google Scholar
|
|
127
|
Li Z, Suo B, Long G, Gao Y, Song J, Zhang
M, Feng B, Shang C and Wang D: Exosomal miRNA-16-5p derived from M1
macrophages enhances T cell-dependent immune response by regulating
PD-L1 in gastric cancer. Front Cell Dev Biol. 8:5726892020.
View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Miliotis C and Slack FJ: miR-105-5p
regulates PD-L1 expression and tumor immunogenicity in gastric
cancer. Cancer Lett. 518:115–126. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Wang W, Sun J, Li F, Li R, Gu Y, Liu C,
Yang P, Zhu M, Chen L, Tian W, et al: A frequent somatic mutation
in CD274 3′-UTR leads to protein over-expression in gastric cancer
by disrupting miR-570 binding. Hum Mutat. 33:480–484. 2012.
View Article : Google Scholar
|
|
130
|
Ashizawa M, Okayama H, Ishigame T, Thar
Min AK, Saito K, Ujiie D, Murakami Y, Kikuchi T, Nakayama Y, Noda
M, et al: miRNA-148a-3p regulates immunosuppression in DNA mismatch
repair-deficient colorectal cancer by targeting PD-L1. Mol Cancer
Res. 17:1403–1413. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Roshani Asl E, Rasmi Y and Baradaran B:
MicroRNA-124-3p suppresses PD-L1 expression and inhibits
tumorigenesis of colorectal cancer cells via modulating STAT3
signaling. J Cell Physiol. 236:7071–7087. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Xu YJ, Zhao JM, Ni XF, Wang W, Hu WW and
Wu CP: LncRNA HCG18 suppresses CD8+ T cells to confer
resistance to cetuximab in colorectal cancer via miR-20b-5p/PD-L1
axis. Epigenomics. 13:1281–1297. 2021.PubMed/NCBI
|
|
133
|
Whiteside TL: The role of regulatory T
cells in cancer immunology. Immunotargets Ther. 4:159–171. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Cai J, Wang D, Zhang G and Guo X: The role
Of PD-1/PD-L1 axis in treg development and function: Implications
for cancer immunotherapy. Onco Targets Ther. 12:8437–8445. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Li S, Wu T, Zhang D, Sun X and Zhang X:
The long non-coding RNA HCG18 promotes the growth and invasion of
colorectal cancer cells through sponging miR-1271 and upregulating
MTDH/Wnt/β-catenin. Clin Exp Pharmacol Physiol. 47:703–712. 2020.
View Article : Google Scholar
|
|
136
|
Bian W, Li Y, Zhu H, Gao S, Niu R, Wang C,
Zhang H, Qin X and Li S: miR-493 by regulating of c-Jun targets
Wnt5a/PD-L1-inducing esophageal cancer cell development. Thorac
Cancer. 12:1579–1588. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Javadrashid D, Mohammadzadeh R,
Baghbanzadeh A, Safaee S, Amini M, Lotfi Z, Baghbani E, Khaze
Shahgoli V and Baradaran B: Simultaneous microRNA-612 restoration
and 5-FU treatment inhibit the growth and migration of human PANC-1
pancreatic cancer cells. EXCLI J. 20:160–173. 2021.PubMed/NCBI
|
|
138
|
Cioffi M, Trabulo SM, Vallespinos M, Raj
D, Kheir TB, Lin ML, Begum J, Baker AM, Amgheib A, Saif J, et al:
The miR-25-93-106b cluster regulates tumor metastasis and immune
evasion via modulation of CXCL12 and PD-L1. Oncotarget.
8:21609–21625. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Wang Y and Cao K: KDM1A promotes
immunosuppression in hepatocellular carcinoma by regulating PD-L1
through demethylating MEF2D. J Immunol Res. 2021:99650992021.
View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Incorvaia L, Fanale D, Badalamenti G,
Brando C, Bono M, De Luca I, Algeri L, Bonasera A, Corsini LR,
Scurria S, et al: A 'lymphocyte MicroRNA signature' as predictive
biomarker of immunotherapy response and plasma PD-1/PD-L1
expression levels in patients with metastatic renal cell carcinoma:
Pointing towards epigenetic reprogramming. Cancers (Basel).
12:33962020. View Article : Google Scholar
|
|
141
|
Adil MS, Khulood D and Somanath PR:
Targeting Akt-associated microRNAs for cancer therapeutics. Biochem
Pharmacol. 189:1143842021. View Article : Google Scholar :
|
|
142
|
Xue J, Yang J, Luo M, Cho WC and Liu X:
MicroRNA-targeted therapeutics for lung cancer treatment. Expert
Opin Drug Discov. 12:141–157. 2017. View Article : Google Scholar
|
|
143
|
Pal S, Garg M and Pandey AK: Deciphering
the mounting complexity of the p53 regulatory network in
correlation to long non-coding RNAs (lncRNAs) in ovarian cancer.
Cells. 9:5272020. View Article : Google Scholar :
|
|
144
|
Chen X, Tang FR, Arfuso F, Cai WQ, Ma Z,
Yang J and Sethi G: The emerging role of long non-coding RNAs in
the metastasis of hepatocellular carcinoma. Biomolecules.
10:662019. View Article : Google Scholar
|
|
145
|
Vafadar A, Shabaninejad Z, Movahedpour A,
Mohammadi S, Fathullahzadeh S, Mirzaei HR, Namdar A, Savardashtaki
A and Mirzaei H: Long non-coding RNAs as epigenetic regulators in
cancer. Curr Pharm Des. 25:3563–3577. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Yi K, Cui X, Liu X, Wang Y, Zhao J, Yang
S, Xu C, Yang E, Xiao M, Hong B, et al: PTRF/Cavin-1 as a novel
RNA-binding protein expedites the NF-κB/PD-L1 axis by stabilizing
lncRNA NEAT1, contributing to tumorigenesis and immune evasion in
glioblastoma. Front Immunol. 12:8027952022. View Article : Google Scholar
|
|
147
|
Ni W, Mo H, Liu Y, Xu Y, Qin C, Zhou Y, Li
Y, Li Y, Zhou A, Yao S, et al: Targeting cholesterol biosynthesis
promotes anti-tumor immunity by inhibiting long noncoding RNA
SNHG29-mediated YAP activation. Mol Ther. 29:2995–3010. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Fan Y, Dong X, Li M, Liu P, Zheng J, Li H
and Zhang Y: LncRNA KRT19P3 is involved in breast cancer cell
proliferation, migration and invasion. Front Oncol. 11:7990822022.
View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Zhang M, Wang N, Song P, Fu Y, Ren Y, Li Z
and Wang J: LncRNA GATA3-AS1 facilitates tumour progression and
immune escape in triple-negative breast cancer through
destabilization of GATA3 but stabilization of PD-L1. Cell Prolif.
53:e128552020. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Shang A, Wang W, Gu C, Chen C, Zeng B,
Yang Y, Ji P, Sun J, Wu J, Lu W, et al: Long non-coding RNA HOTTIP
enhances IL-6 expression to potentiate immune escape of ovarian
cancer cells by upregulating the expression of PD-L1 in
neutrophils. J Exp Clin Cancer Res. 38:4112019. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Chen Y, Li F, Li D, Liu W and Zhang L:
Atezolizumab and blockade of LncRNA PVT1 attenuate cisplatin
resistant ovarian cancer cells progression synergistically via
JAK2/STAT3/PD-L1 pathway. Clin Immunol. 227:1087282021. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Huang Y, Xia L, Tan X, Zhang J, Zeng W,
Tan B, Yu X, Fang W and Yang Z: Molecular mechanism of lncRNA
SNHG12 in immune escape of non-small cell lung cancer through the
HuR/PD-L1/USP8 axis. Cell Mol Biol Lett. 27:432022. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Shi L, Yang Y, Li M, Li C, Zhou Z, Tang G,
Wu L, Yao Y, Shen X, Hou Z and Jia H: LncRNA IFITM4P promotes
immune escape by up-regulating PD-L1 via dual mechanism in oral
carcinogenesis. Mol Ther. 30:1564–1577. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Wang Y, Yi K, Liu X, Tan Y, Jin W, Li Y,
Zhou J, Wang H and Kang C: HOTAIR up-regulation activates NF-κB to
induce immunoescape in gliomas. Front Immunol. 12:7854632021.
View Article : Google Scholar
|
|
155
|
Atianand MK, Hu W, Satpathy AT, Shen Y,
Ricci EP, Alvarez-Dominguez JR, Bhatta A, Schattgen SA, McGowan JD,
Blin J, et al: A long noncoding RNA lincRNA-EPS acts as a
transcriptional brake to restrain inflammation. Cell.
165:1672–1685. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Mineo M, Lyons SM, Zdioruk M, von
Spreckelsen N, Ferrer-Luna R, Ito H, Alayo QA, Kharel P, Giantini
Larsen A, Fan WY, et al: Tumor interferon signaling is regulated by
a lncRNA INCR1 transcribed from the PD-L1 locus. Mol Cell.
78:1207–1223.e8. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Xu J, Meng Q, Li X, Yang H, Xu J, Gao N,
Sun H, Wu S, Familiari G, Relucenti M, et al: Long noncoding RNA
MIR17HG promotes colorectal cancer progression via miR-17-5p.
Cancer Res. 79:4882–4895. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Yin L, Tang Y and Yuan Y: An overview of
the advances in research on the molecular function and specific
role of circular RNA in cardiovascular diseases. Biomed Res Int.
2022:51541222022. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Verduci L, Tarcitano E, Strano S, Yarden Y
and Blandino G: CircRNAs: Role in human diseases and potential use
as biomarkers. Cell Death Dis. 12:4682021. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Dong W, Dai ZH, Liu FC, Guo XG, Ge CM,
Ding J, Liu H and Yang F: The RNA-binding protein RBM3 promotes
cell proliferation in hepatocellular carcinoma by regulating
circular RNA SCD-circRNA 2 production. EBioMedicine. 45:155–167.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Wang L, Yi J, Lu LY, Zhang YY, Wang L, Hu
GS, Liu YC, Ding JC, Shen HF, Zhao FQ, et al: Estrogen-induced
circRNA, circPGR, functions as a ceRNA to promote estrogen
receptor-positive breast cancer cell growth by regulating cell
cycle-related genes. Theranostics. 11:1732–1752. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Wang S, Qian L, Cao T, Xu L, Jin Y, Hu H,
Fu Q, Li Q, Wang Y, Wang J, et al: Advances in the study of
CircRNAs in tumor drug resistance. Front Oncol. 12:8683632022.
View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Li C, Zhang J, Yang X, Hu C, Chu T, Zhong
R, Shen Y, Hu F, Pan F, Xu J, et al: hsa_circ_0003222 accelerates
stemness and progression of non-small cell lung cancer by sponging
miR-527. Cell Death Dis. 12:8072021. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Feinberg AP: The key role of epigenetics
in human disease prevention and mitigation. N Engl J Med.
378:1323–1334. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Srivastava R and Lodhi N: DNA methylation
malleability and dysregulation in cancer progression: Understanding
the role of PARP1. Biomolecules. 12:4172022. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Emran AA, Chatterjee A, Rodger EJ, Tiffen
JC, Gallagher SJ, Eccles MR and Hersey P: Targeting DNA methylation
and EZH2 activity to overcome melanoma resistance to immunotherapy.
Trends Immunol. 40:328–344. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Lv D, Xing C, Cao L, Zhuo Y, Wu T and Gao
N: PD-L1 gene promoter methylation represents a potential
diagnostic marker in advanced gastric cancer. Oncol Lett.
19:1223–1234. 2020.PubMed/NCBI
|
|
168
|
Del Castillo Falconi VM, Torres-Arciga K,
Matus-Ortega G, Díaz-Chávez J and Herrera LA: DNA
methyltransferases: From evolution to clinical applications. Int J
Mol Sci. 23:89942022. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Lu X, Li Y, Yang W, Tao M, Dai Y, Xu J and
Xu Q: Inhibition of NF-κB is required for oleanolic acid to
downregulate PD-L1 by promoting DNA demethylation in gastric cancer
cells. J Biochem Mol Toxicol. 35:e226212021. View Article : Google Scholar
|
|
170
|
Liu J, Liu Y, Meng L, Liu K and Ji B:
Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib
in human hepatocellular carcinoma. Oncol Rep. 38:899–907. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Chatterjee A, Rodger EJ, Ahn A, Stockwell
PA, Parry M, Motwani J, Gallagher SJ, Shklovskaya E, Tiffen J,
Eccles MR and Hersey P: Marked global DNA hypomethylation is
associated with constitutive PD-L1 expression in melanoma.
iScience. 4:312–325. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Peng D, Kryczek I, Nagarsheth N, Zhao L,
Wei S, Wang W, Sun Y, Zhao E, Vatan L, Szeliga W, et al: Epigenetic
silencing of TH1-type chemokines shapes tumour immunity and
immunotherapy. Nature. 527:249–253. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Li X, Wang Z, Huang J, Luo H, Zhu S, Yi H,
Zheng L, Hu B, Yu L, Li L, et al: Specific zinc finger-induced
methylation of PD-L1 promoter inhibits its expression. FEBS Open
Bio. 9:1063–1070. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Garg M: Epithelial-mesenchymal
transition-activating transcription factors-multifunctional
regulators in cancer. World J Stem Cells. 5:188–195. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Asgarova A, Asgarov K, Godet Y, Peixoto P,
Nadaradjane A, Boyer-Guittaut M, Galaine J, Guenat D, Mougey V,
Perrard J, et al: PD-L1 expression is regulated by both DNA
methylation and NF-kB during EMT signaling in non-small cell lung
carcinoma. Oncoimmunology. 7:e14231702018. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Zhang Y, Xiang C, Wang Y, Duan Y, Liu C
and Zhang Y: PD-L1 promoter methylation mediates the resistance
response to anti-PD-1 therapy in NSCLC patients with EGFR-TKI
resistance. Oncotarget. 8:101535–101544. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Lai Q, Wang H, Li A, Xu Y, Tang L, Chen Q,
Zhang C, Gao Y, Song J and Du Z: Decitibine improve the efficiency
of anti-PD-1 therapy via activating the response to IFN/PD-L1
signal of lung cancer cells. Oncogene. 37:2302–2312. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Mu L, Long Y, Yang C, Jin L, Tao H, Ge H,
Chang YE, Karachi A, Kubilis PS, De Leon G, et al: The IDH1
mutation-induced oncometabolite, 2-hydroxyglutarate, may affect DNA
methylation and expression of PD-L1 in gliomas. Front Mol Neurosci.
11:822018. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Briand J, Nadaradjane A, Bougras-Cartron
G, Olivier C, Vallette FM and Cartron PF: Diuron exposure and Akt
overexpression promote glioma formation through DNA
hypomethylation. Clin Epigenetics. 11:1592019. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Elashi AA, Sasidharan Nair V, Taha RZ,
Shaath H and Elkord E: DNA methylation of immune checkpoints in the
peripheral blood of breast and colorectal cancer patients.
Oncoimmunology. 8:e15429182018. View Article : Google Scholar
|
|
181
|
Jacot W, Lopez-Crapez E, Mollevi C,
Boissière-Michot F, Simony-Lafontaine J, Ho-Pun-Cheung A, Chartron
E, Theillet C, Lemoine A, Saffroy R, et al: BRCA1 promoter
hypermethylation is associated with good prognosis and
chemosensitivity in triple-negative breast cancer. Cancers (Basel).
12:8282020. View Article : Google Scholar
|
|
182
|
Yamada R, Yamaguchi T, Iijima T, Wakaume
R, Takao M, Koizumi K, Hishima T and Horiguchi SI: Differences in
histological features and PD-L1 expression between sporadic
microsatellite instability and Lynch-syndrome-associated disease in
Japanese patients with colorectal cancer. Int J Clin Oncol.
23:504–513. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Hua S, Gu M, Wang Y, Ban D and Ji H:
Oxymatrine reduces expression of programmed death-ligand 1 by
promoting DNA demethylation in colorectal cancer cells. Clin Transl
Oncol. 23:750–756. 2021. View Article : Google Scholar
|
|
184
|
Liu Z, Ren Y, Weng S, Xu H, Li L and Han
X: A new trend in cancer treatment: The combination of epigenetics
and immunotherapy. Front Immunol. 13:8097612022. View Article : Google Scholar : PubMed/NCBI
|
